pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
793
stories
Sep 21, 26
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
Sep 21, 26
Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
biospace
Sep 21, 26
Novo buys three early-stage obesity assets from Kallyope as investor pressure mounts
biospace
Sep 21, 26
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
Sep 21, 26
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
fiercebiotech
Sep 18, 26
FDA approves Lilly's oral SERD combo for second-line breast cancer therapy
endpoints
Sep 18, 26
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
Sep 18, 26
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope
fiercebiotech
Sep 17, 26
Novo partners with Orbis, deepening investment in oral peptide drugs
biopharma dive
Sep 17, 26
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
Sep 17, 26
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
Sep 17, 26
Fed rate hike won’t hold biotech down despite climbing capital costs
biospace
Sep 17, 26
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
biospace
Sep 17, 26
DPHARM: How to address the clinical trial enrollment crisis?
fiercebiotech
Sep 17, 26
Lilly-backed Orbis does up to $1.4B macrocycle deal with Novo
endpoints
Sep 17, 26
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
Sep 17, 26
Trending: Top biopharma disciplines with jobs live now
biospace
Sep 17, 26
Biopharma hiring hotspots: States, disciplines where demand is highest
biospace
Sep 16, 26
'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand
fiercebiotech
Sep 16, 26
Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
biopharma dive
Sep 16, 26
Deep dive: Psychedelics back on FDA’s doorstep
biospace
Sep 16, 26
Why a US senator wants a biotech leader in the White House who ‘has the president’s ear’
fiercebiotech
Sep 16, 26
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
fiercebiotech
Sep 15, 26
FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharma dive
Sep 15, 26
Rocket's Danon plans; Novo leaves Ascendis; Lilly's latest deal
endpoints
Sep 15, 26
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
fiercebiotech
Sep 14, 26
Electra aims for nearly $300M IPO; Enhertu's Phase 3 lung cancer success
endpoints
Sep 14, 26
Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand
biospace
Sep 14, 26
AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market
biospace
Sep 14, 26
Lilly cans early experimental obesity drug after ‘high bar’ not met
fiercebiotech
← prev
page 9 of 27
next →
